Modified PUFAs - A unique drug concept

In Biozep we are using advanced synthetic and biochemical methods to optimize the structure of polyunsaturated fatty acids (PUFAs) to make them more target selective, more potent and improve their metabolic stability. This structure optimization has resulted in novel drug substances which can be used in the treatment of a variety of metabolic, inflammatory and age-related diseases. Because of their natural origin, their toxic effects are negligible compared to synthetic small drug molecules, making them superior candidates for long dosing regimens in the treatment of chronic disease.

Successful Drug Discovery Program

Biozep has an ongoing drug discovery program to design modified PUFAs with selective and potent affinity to receptors regulating  energy metabolism, inflammation and redox homeostasis.  We have established a novel screening platform to identify PUFAs with higher affinity to these receptors compared to the PUFAs. In addition the modified PUFAs are tested in assays measuring effects on cell metabolism, inflammation and redox homeostasis. ​​

Based on results from our drug discovery program we have selected a lead candidate named BIZ-101, which we believe can be used to treat chronic inflammatory eye diseases. The hypothesis is strongly backed by data showing that BIZ-101 effectively inhibit the NF-kB signalling pathway and protect different cell types from damage caused by oxidative stress. ​
​

Novel Formulation

Topical eye drops are the mainstay of therapy for many eye diseases. Due to the high lipophilicity of our drug molecules, standard water-based formulations can not be used.  Biozep has developed a preclinical formulation  which is customized for modified PUFAs. The formulation is non-viscous, water-free, and spreads rapidly on the occular suface.